BIO Ventures for Global Health (BVGH); March 2012
“…Understanding the neglected disease R&D pipeline as well as the spectrum of organizations participating in the development of these new drugs and vaccines is essential to evaluating the efficiency and effectiveness of current R&D programs — and to inform the design of new ones. Until now, this type of analysis has been hindered in part because neglected disease pipelines have not been systematically tracked or analyzed. Recognizing this…BVGH collected and reviewed data from our Global Health Primer to — for the first time — shed light on the different types of organizations that are participating in product development for a broad range of neglected diseases…academic and research institutions participate in 43% of all neglected disease products in development. That participation is broad and deep but often under recognized. Product development partnerships, or PDPs, support approximately 40% of the overall neglected disease pipeline. Industry participation in product development is similar for products with and without PDP development partners. We note in the report that these findings are quantitative and do not reflect the scope and depth of the valuable work produced by these organizations through the R&D work they have undertaken…”
vaccines and global health :: ethics and policy 